+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
From
From
Recurrent Or Metastatic Head And Neck Cancer Market - Product Thumbnail Image

Recurrent Or Metastatic Head And Neck Cancer Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
From
Strategic Intelligence: Immuno-oncology (2025) - Product Thumbnail Image

Strategic Intelligence: Immuno-oncology (2025)

  • Report
  • July 2025
  • 163 Pages
  • Global
From
From
From
Bispecific Antibody & Cancer Patent Landscape Analysis - Product Thumbnail Image

Bispecific Antibody & Cancer Patent Landscape Analysis

  • Report
  • January 2025
  • 120 Pages
  • Global
From
From
CD137 Antibodies Clinical Trials & Market Opportunity Insight - Product Thumbnail Image

CD137 Antibodies Clinical Trials & Market Opportunity Insight

  • Report
  • September 2024
  • 210 Pages
  • Global
From
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more